The treatment of direct spinal disease with biological agents is a viable and, in many cases, very effective treatment.
It is a chronic inflammatory disease with a major heaviness and axle bones, such as the spinal column and the hip, which can also affect the outer joint. Traditional drug treatment, which includes inflammatory and rheumatological drugs, has a role in controlling symptoms and progression, but some patients are ineffective. The emergence of biological agents provides new hope for these patients.
The principle of biological agents for the treatment of direct spinal disease is primarily the key inflammation factor in the disease ‘ s onset. For example, tumour cause of death – α (TNF – α) constrictor – is a commonly used type of biological agent. TNF-alpha overexpression in patients with direct spina, which stimulates the growth of membrane cells and induces inflammation, thereby perpetuating inflammation around joints and spines, causing pain, rigidity and joint damage. TNF-alpha resistance can be accurately combined with TNF-alpha to prevent inflammation, thereby rapidly reducing inflammation response.
In terms of clinical effects, biological agents have performed well in mitigating symptoms. Many patients, using biological agents, have a clear sense of spinal and joint pain, and early-morning rigidities have been rapidly reduced. Such relief is usually more significant and rapid than traditional medicines. Studies have shown that after several weeks of treatment with biological agents, most patients can reduce their pain levels by more than 50 per cent, with significantly reduced morning rigidities and significant improvements in their mobility and quality of life.
Biological agents also play a key role in controlling the progress of diseases. If it is not effectively controlled, it will gradually lead to vertical and joint deformities. Biological agents can effectively contain the erosion of spinal and joints by inflammation and reduce the incidence of spinal symbiotic changes and joints integration. For patients with long-term use of biological agents, a visual examination shows that progress in the pathology of the spinal and joints has been significantly delayed and is significant for protecting the function of the joints and spines.
However, the treatment of biological agents is not perfect. On the one hand, it is relatively expensive, which may place a financial burden on patients. On the other hand, there are risks associated with the use of biological agents. Because biological agents inhibit part of the immune system, patients may increase the risk of infection, such as respiratory infections, tuberculosis infections, etc. In addition, a small number of patients may be allergic or have anti-drugs that affect treatment effectiveness.
In order to ensure the safety and effectiveness of the treatment of biological agents, a comprehensive assessment of the patient is required prior to use. Checks include patient history of infection, test of tuberculosis fungus, etc., to exclude potential risk of infection. In the course of treatment, patients also need to work closely with doctors to conduct regular reviews to monitor the adverse effects of drugs and the progress of diseases.
Biological agent treatment is feasible for people with direct spina syndrome, but needs to be considered in the context of its efficacy, risks and economic costs. Among the appropriate patients, biological agents can significantly improve their condition and are an important treatment that deserves consideration.
